Skip to main content

Table 2 Mutational rate of most frequently altered genes in CRC in HM, HM-like and non-HM group

From: An integrative in-silico analysis discloses a novel molecular subset of colorectal cancer possibly eligible for immune checkpoint immunotherapy

Genes

Pathway

HM (%)

HM-like (%)

Non-HM (%)

P value

APC

WNT signaling

49

59

84

***

AMER1

WNT signaling

27

15

9

***

CTNNB1

WNT signaling

24

12

3

***

TCF7L2

WNT signaling

24

0

7

***

FBXW7

WNT signaling

40

32

11

***

ARID1A

WNT signaling

45

5

6

***

SOX9

WNT signaling

15

27

11

*

TGFBR2

TGF-β signaling

12

7

1

NS

ACVR2A

TGF-β signaling

37

15

1

**

SMAD4

TGF-β signaling

15

17

12

NS

PIK3CA

PIK3 signaling

40

41

21

***

PTEN

PIK3 signaling

22

10

3

**

FAT4

Hippo signaling pathway

76

24

15

***

ERBB2

MAPK signaling

15

5

2

***

ERBB3

MAPK signaling

22

5

2

***

KRAS

MAPK signaling

26

59

41

***

NRAS

MAPK signaling

4

7

7

NS

BRAF

MAPK signaling

62

12

3

***

ATM

DNA damage response

50

10

7

***

TP53

DNA damage response

29

15

69

***

LRP1B

Membrane trafficking

53

5

13

***

KMT2D

Histone methyl transferase

64

15

3

***